Bulgaria Country Drug Report 2018

Public expenditure

Understanding the costs of drug-related actions is an important aspect of drug policy. Some of the funds allocated by governments to expenditure on tasks related to drugs are identified as such in the budget (‘labelled’). Often, however, most drug-related expenditure is not identified (‘unlabelled’) and must be estimated using modelling approaches.

Although the financing of drug-related activities in Bulgaria is decided annually by the entities in charge of their implementation, coordination between central and local government plays an important role. In addition, according to the National Anti-Drug Strategies (for both 2009-13 and 2014-18), national programming documents have been important guides for the planning of public financing for drug-related initiatives. Estimates for drug-related public expenditure are reported; however, it is not possible to assess what proportion of the total amount spent is represented by those estimates. Preliminary estimates indicate that, in 2015, a total of BGN 3 892 496 (EUR 1 990 232) was allocated for labelled drug-related expenditure, which represented about 0.01 % of gross domestic product.


Bulgaria main page

Methodological note: Analysis of trends is based only on those countries providing sufficient data to describe changes over the period specified. The reader should also be aware that monitoring patterns and trends in a hidden and stigmatised behaviour like drug use is both practically and methodologically challenging. For this reason, multiple sources of data are used for the purposes of analysis in this report. Caution is therefore required in interpretation, in particular when countries are compared on any single measure. Detailed information on methodology and caveats and comments on the limitations in the information set available can be found in the EMCDDA Statistical Bulletin.